The epidemiologic burden of hepatitis C virus infection in Latin America
Journal Title: Annals of Hepatology - Year 2012, Vol 11, Issue 5
Abstract
Chronic infection with hepatitis C virus (HCV) is a major and growing public health concern worldwide, including in Latin America. With more efficacious therapies becoming available, decision-makers will require accurate estimates of disease prevalence to assess the potential impact of new treatments. However, few estimates of the epidemiologic burden, either overall or by country, are available for Latin America; and the potential impact of currently-available treatments on the epidemiologic burden of HCV in Latin America has not been assessed. To address this, we systematically reviewed twenty-five articles presenting population-based estimates of HCV prevalence from general population or blood donor samples, and supplemen-ted those with publically-available data, to estimate the total number of persons infected with HCV in Latin America at 7.8 million (2010). Of these, over 4.6 million would be expected to have genotype 1 chronic HCV, based on published data on the risk of progression to chronic disease and the HCV genotype distribution of Latin America. Finally, we calculated that between 1.6 and 2.3 million persons with genotype 1 chronic HCV would potentially benefit from current treatments, based on published estimates of genotype-specific treatment responsiveness. In conclusion, these estimates demonstrate the substantial present epidemiologic burden of HCV, and quantify the impending societal and clinical burden from untreated HCV in Latin America.
Authors and Affiliations
Shelagh Szabo, Meagan Bibby, Yong Yuan, Bonnie Donato, R. Jiménez-Mendez, Maribel Rodríguez-Torres, G. Castañeda-Hernández, Adrian Levy
Keywords
Related Articles
- EP ID EP78183
- DOI -
- Views 118
- Downloads 0
Budd Chiari syndrome without evidence for thrombosis. Is it still a Budd Chiari ?
Subzero nonfreezing storage of rat hepatocytes using modified University of Wisconsin solution (mUW) and 1,4-butanediol. I- effects on cellular metabolites during cold storage
Various cryopreservation techniques have been investigated to extend the storage of isolated hepatocytes; however, most have a reduced viability after rewarming due to ice crystal formation. Subzero nonfreezing condition...
NASH and cryptogenic cirrhosis: A histological analysis†
Introduction. Epidemiological studies indicate that nonalcoholic steatohepatitis (NASH) is a common cause of cirrhosis described as ‘cryptogenic’. To address this from a histological perspective and to examine the signif...
Clear cell hepatocellular carcinoma arising 25 years after the successful treatment of an infantile hepatoblastoma
Primary liver tumors in children are rare with hepatoblastoma (HB) being the most common malignancy. Clear cell carcinoma, a variant of hepatocellular carcinoma (HCC), is another rare tumor of the liver that tends to aff...
Predictors and impacts of hospital readmissions following liver transplantation
While liver transplantation is the definitive therapy for end stage liver disease, it remains a major procedure, with many potential complications. Hospital readmissions after the initial hospitalization for liver trans...